Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 13, 2024MetabolitesOpen Access

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJan P. KleinjanJBJustin BlomABAndré P. van Beek

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kleinjan et al. (2024) studied this question.

synapsesocial.com/papers/68e7445fb6db6435876bdb2ehttps://doi.org/10.3390/metabo14030162
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials2022 · 53 citations
  2. 2Sodium‐glucose co‐transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials2016 · 77 citations
  3. 3Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor2017 · 337 citations
  4. 4Hyperglycemic Crises in Adult Patients With Diabetes2009 · 2,084 citations
  5. 5SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study2023 · 103 citations